We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05464719
Recruitment Status : Recruiting
First Posted : July 19, 2022
Last Update Posted : September 26, 2022
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.

Condition or disease Intervention/treatment Phase
Large B-cell Lymphoma Lymphoma Drug: Loncastuximab Tesirine Phase 2

Detailed Description:

Primary Objective:

-To evaluate the efficacy of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.

Secondary Objectives:

-To evaluate safety and tolerability of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.

Exploratory Objective:

-To determine the pharmacodynamic effects and investigate biomarkers of response and resistance of this novel consolidation therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Actual Study Start Date : September 23, 2022
Estimated Primary Completion Date : January 30, 2026
Estimated Study Completion Date : January 30, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Loncastuximab Tesirine
Participants will receive Loncastuximab Tesirine (lonca) by vein.
Drug: Loncastuximab Tesirine
Given by IV
Other Name: Lonca

Primary Outcome Measures :
  1. Rate of conversion to complete response [ Time Frame: through study completion and or average of 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Eligible subjects will be considered for inclusion in this study if they meet the following criteria:

  1. Relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed indolent B-cell lymphomas and high-grade B-cell lymphoma
  2. Receive standard of care treatment with an FDA-approved anti-CD19 autologous CAR T-cell product, outside of a clinical trial
  3. ≥ 18 years of age
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  5. Achievement of PR according to Lugano 2014 response criteria 30 days after CAR T-cell therapy
  6. At least 30 days must have elapsed since CAR T-cell therapy infusion
  7. No evidence of CD19 expression after CAR T-cell therapy infusion is required for enrolment
  8. No additional anti-tumoral therapy, with the exclusion of palliative radiotherapy, must have been received after CAR T-cell therapy
  9. Absolute neutrophil count of ≥ 1.0×109/L without growth factor support for 7 days prior to screening assessment.
  10. Platelet count of ≥ 50×109/L without transfusion for 7 days prior to screening assessment
  11. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
  12. Serum alanine transaminase (ALT), aspartate transaminase (AST) or gamma glutamyl transferase (GGT) ≤ 2.5 upper limit of normal (ULN)
  13. Total bilirubin ≤2 mg/dL, except in subjects with Gilbert's syndrome.
  14. Cardiac ejection fraction ≥ 45% with no evidence of clinically significant pericardial effusion
  15. Baseline oxygen saturation > 92% on room air
  16. No evidence or suspicion of lymphoma actively involving the central nervous system (CNS)
  17. Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
  18. Resolution of any previous CRS and/or ICANS to grade 0.

Exclusion criteria:

Subjects will be ineligible for this study if they meet the following criteria:

  1. Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
  2. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. prostate, cervix, bladder, breast) unless disease free for at least 12 months
  3. History of Richter's transformation of chronic lymphocytic leukemia (CLL)
  4. Treatment with CAR T-cell therapy on clinical trial as immediate treatment before enrollment
  5. Prior treatment with lonca
  6. Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Principal investigator
  7. Known history of infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive). A history of HIV, hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative PCR and/or nucleic acid testing.
  8. Subjects with active cardiac atrial or cardiac ventricular lymphoma involvement
  9. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrolment
  10. Primary immunodeficiency
  11. History of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring active systemic immunosuppression/systemic disease modifying agents within the last 2 years
  12. History of clinically significant deep vein thrombosis or pulmonary embolism within 6 months of enrolment
  13. Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
  14. History of severe immediate hypersensitivity reaction to any of the agents used in this study
  15. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the PBD on the fetus or infant.
  16. Subjects of both genders who are not willing to practice birth control. Women of childbearing potential must use a highly effective method of contraception (hormonal birth control such as birth control pills, intravaginal ring, skin patch, implant or injection, intrauterine device or surgical sterilization) until 9 months after last dose of lonca, and men with female partners who are of childbearing potential should use a condom when sexually active until 6 months after the last dose of lonca
  17. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participationTrial Treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05464719

Layout table for location contacts
Contact: Paolo Strati, MD (713) 745-1776 pstrati@mdanderson.org

Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Paolo Strati, MD    713-745-1776    pstrati@mdanderson.org   
Principal Investigator: Paolo Strati, MD         
Sponsors and Collaborators
M.D. Anderson Cancer Center
Layout table for investigator information
Principal Investigator: Paolo Strati, MD M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT05464719    
Other Study ID Numbers: 2022-0147
NCI-2022-05750 ( Other Identifier: NCI-CTRP Clinical Trials Reporting Registry )
First Posted: July 19, 2022    Key Record Dates
Last Update Posted: September 26, 2022
Last Verified: September 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Loncastuximab tesirine
Antineoplastic Agents, Immunological
Antineoplastic Agents